We use cookies on this website. By continuing to use this site without changing your cookie settings, you agree that you are happy to accept our privacy policy and for us to access our cookies on your device.
Title:Korean Health Stocks' Rising Valuations Worrying: Dalton
Date:10th July 2020
Description:Jul.10 -- James Lim, senior research analyst at the $3 billion California-based hedge fund Dalton Investments LCC, discusses the outlook for South Korean stocks and corporate governance. Lim has warned that retail investors could pull out of the nation’s equity market on unforeseen events such as an earlier-than-expected curb in the Covid-19 pandemic or a lifting of a short-sell ban. Drug-related shares are especially vulnerable because hopes for a virus cure have made them expensive, according to Lim. He speaks on "Bloomberg Markets: Asia."
